Stock-Based Compensation (Annual)

Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.

Eagle Pharmaceuticals, Inc. (EGRX) had Stock-Based Compensation of $16.45M for the most recently reported fiscal year, ending 2022-12-31.

Quarterly Annual

Figures for fiscal year ending 2022-12-31

Income Statement Financials
Revenue	$316.61M
Net Income	$35.64M
Cost of Goods Sold	$94.94M
Gross Profit	$221.67M
Operating Expenses	$235.65M
Operating Income	$80.96M
Non-Operating Income/Expense	$-19.53M
Pre-Tax Income	$61.43M
Normalized Pre-Tax Income	$61.43M
Income after Taxes	$35.64M
Income from Continuous Operations	$35.64M
Consolidated Net Income/Loss	$35.64M
Normalized Income after Taxes	$35.64M
EBIT	$80.96M
EBITDA	$94.70M
Weighted-Average Shares Outstanding (Basic)	12.93M
Weighted-Average Shares Outstanding (Diluted)	13.06M
Earnings per Share (EPS) (Basic)	$2.76
Earnings per Share (EPS) (Diluted)	$2.73
Balance Sheet Financials
Current Assets	$188.75M
Property, Plant, and Equipment	$1.17M
Long-Term Assets	$217.41M
Total Assets	$406.16M
Current Liabilities	$111.09M
Long-Term Debt	$56.22M
Long-Term Liabilities	$61.51M
Total Liabilities	$172.60M
Common Equity	$233.56M
Tangible Shareholders Equity	$70.20M
Shareholders Equity	$233.56M
Common Shares Outstanding	13.02M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$50.70M
Cash Flow from Investing Activities	$-86.83M
Cash Flow from Financial Activities	$-6.21M
Beginning Cash	$97.66M
End Cash	$55.32M
Increase/Decrease in Cash	$-42.34M
Stock-Based Compensation	$16.45M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	1.70
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.19
Debt to Equity Ratio	0.27
Gross Margin	70.01%
Operating Margin	25.57%
EBIT Margin	25.57%
EBITDA Margin	29.91%
Pre-Tax Profit Margin	19.40%
Profit Margin	11.26%
Free Cash Flow	$50.52M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.78
Inventory Turnover	1.99
Receiveable Turnover	4.37
Days Sales in Receivables	83.51
Return on Equity	15.26%
Return on Tangible Equity	50.77%
Return on Assets	8.78%
Return on Investments	12.30%
Book Value Per Share	$17.94
Free Cash Flow per Share	$3.87
Operating Cash Flow per Share	$3.88

Data from Zacks Investment Research, Inc.